On Tuesday, Abcellera Biologics Inc received a positive adjustment to its Relative Strength (RS) Rating, from 70 to 76.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves. See if Abcellera Biologics Inc can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
While now is not an ideal time to invest, see if the stock is able to establish and enter a buying range in heavy volume. On a positive note, the stock has cleared all but one key moving average, holding its own in a tough market environment.
Earnings News
Earnings growth decreased in the most recent report from 46% to -100%. But revenue gains moved higher, from 56% to 66%. The next quarterly results are expected on or around Nov. 9.
Abcellera Biologics Inc holds the No. 96 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals and Genmab are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
